The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.

M. A. Dimopoulos

Consultant or Advisory Role - Ortho Biotech

Honoraria - Celgene; Janssen-Cilag; Merck Sharp & Dohme; Millennium; Ortho Biotech

R. Z. Orlowski

Consultant or Advisory Role - Celgene; Millennium

Research Funding - Celgene; Millennium

R. Niesvizky

Consultant or Advisory Role - Celgene; Millennium; Onyx

Honoraria - Celgene; Millennium; Novartis

Research Funding - Celgene; Millennium; Onyx; Onyx

S. Lonial

Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx

Research Funding - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx

N. A. Brandenburg

Employment or Leadership Position - Celgene

D. M. Weber

Consultant or Advisory Role - Merck (U); Novartis (U)

Honoraria - Celgene; Millennium

Research Funding - Celgene; Merck; Millennium